NCT03485547 - Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

February 17, 2026

Study Completion Date

February 17, 2026

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions

DRUG

Venetoclax

VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct

Trial Locations (2)

77030

MD Anderson Cancer Center, Houston

02215

Dana Farber Cancer Institute, Boston